SLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Silence Therapeutics PLC (SLN) is not a good buy for a beginner, long-term investor at this time. The company is facing significant financial challenges, with declining revenue, net income, and EPS. Additionally, there are no strong positive catalysts or trading signals to justify an immediate investment. The technical indicators and options data do not suggest a strong entry point, and the stock's recent performance and outlook remain weak.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 52.547, suggesting no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot level of 5.622, with resistance at 6.246 and support at 4.998. Overall, the technical indicators do not signal a strong buy opportunity.
The company is exploring innovative therapies and strategic partnerships to improve its financial situation, which could potentially lead to future growth.
Gross margin also dropped significantly (-141.81% YoY), indicating financial instability. Recent news highlights cautious market sentiment due to these financial challenges.
In Q3 2025, Silence Therapeutics reported a revenue drop of -89.29% YoY to $159,000, a net income drop of -40.33% YoY to -$20.96 million, and an EPS decline of -40.00% YoY to -$0.15. Gross margin also fell drastically to 59.75, down -141.81% YoY. The latest FY GAAP EPS is -$0.63, with revenue of $0.5 million, reflecting ongoing financial struggles.
No recent analyst ratings or price target changes are available for Silence Therapeutics PLC. Market sentiment remains cautious due to the company's financial challenges.
